

INDEX

Note: Page numbers in *italics* indicate figures;
page numbers followed by t indicate tables.

- AACG. See *Acute angle-closure glaucoma*.
- Abdominal pain, from Cosopt and Combigan, 180t
- Acetazolamide (Diamox, Diamox Sequels), 175-178
contraindications and warnings, 175
delivery/dosage, 177t
side effects, 178t, 193t
- Actin cytoskeleton, 194
- Acute angle-closure glaucoma (AACG), 27. See also *Angle-closure glaucoma, primary*.
- Adjunctive/additive therapy, 216, 220
- Adrenergic agonists, nonspecific, 110t, 114, 184-185, 185t. See also *Dipivefrin*.
contraindications, 185
side effects, 185, 186t, 192t
- Advanced Glaucoma Intervention Study (AGIS), 26, 145t, 149-151, 150t
- African Americans
central corneal thickness and, 26, 155
glaucoma incidence and prevalence in, 85-88, 86t, 87, 95
glaucoma progression and, 149
- Age
 β -blocker side effects and, 203
exfoliation syndrome and, 234
glaucoma progression and, 100, 153
incidence/prevalence of POAG and, 85-89, 87
of onset of POAG, 14, 86
pigmentary dispersion syndrome and, 234
therapy aggressiveness and, 136-137
- Ahmed tube implants (shunts), 116-118, 117
- Air-puff tonometer, 23-24
- Algorithm for treatment, 217-220, 218-219
- Allergic follicular conjunctivitis, 171
- Allergic reaction
to α_2 -agonists, 171, 172t
to benzalkonium chloride, 168
to carbonic anhydrase inhibitors, 176t
to dipivefrin, 186t
- Allergies, medications for, 18
- Alpha zone, 34
- α_2 -agonists, 114, 168-171, 169t. See also *specific drugs*.
aqueous humor production/outflow and, 110t, 111, 113t, 114
in combination therapy, 131t, 170, 171
contraindications, 171
dosage, 169t
drug interactions, 171
efficacy, 170-171
indications for, 170
for PACG, 228
for post-trabeculoplasty IOP spike, 237
side effects, 111, 171, 172t-173t
vs timolol, 170-171
- Alphagan. See *Brimonidine*.
- ALT. See *Argon laser trabeculoplasty*.
- Alternative therapies, 191-194
- Altitudinal defect, 49
- Aminoguanidine, 195t, 196-197
- Amsler grid testing, 51
- Amyloid-beta pathway triple combination therapy, 195t, 196-197
- Anecortave acetate, 195t, 198
- Angina pectoris, 167t
- Angle-closure glaucoma, primary (PACG), 225-232, 226
acute, stress and, 27
anterior chamber depth and, 106
ciliary block glaucoma and, 230-231, 231t
diagnosis, 225-227, 227t
drug contraindications and warnings in, 175, 185
- Angle-closure glaucoma, primary (PACG) (*continued*)
gonioscopic detection of, 31, 226
management objective, 228-229
pathogenesis, 106, 225, 226
plateau iris and, 229-230
pupillary block and, 225, 226
signs of, 225, 226
trauma and, 31, 106, 253
treatment, 228-229, 229
- Angle-closure glaucoma, secondary, 254
- Aniridia, 95
- Anorexia, 193t
- Anterior chamber
angles of
gonioscopic examination, 28-31, 30, 227t
grading systems for, 31, 31t
measurements/examination of, 28-31, 30, 226-227
slit-lamp examination, 29t
SPAC depth analyzer, 227
shallow
after filtration surgery, 130t, 243
in ciliary block glaucoma, 230, 230t
management of, 243
in PACG, 106, 225-226, 227t
- Anterior segment inflammation, 238-239
- Anterior segment optical coherence tomography (ASOCT), 226-227
- Anterior uveitis, 238-239
- Anti-angiogenic agents, 195t, 198
- Anti-TNF- α , 195t
- Anti-vascular endothelial growth factor (anti-VEGF), 254-255
- Antibiotics, 243
- Antibodies, 95
- Anticholinergics, 237
- Antifibrosis agents, 241-242
- Antimetabolites, 241-242, 249
- Antioxidants, 191
- Aphakic glaucoma, laser surgery for, 111
- Aplastic anemia, 111, 175
- Apoptosis, 93
protective/inhibiting agents, 196-197
- Appetite, loss of, 178t
- Applanation tonometry, 21-22
- Apraclonidine (Lopidine), 110t, 169t. See also α_2 -agonists.
in combination with beta-blockers, 171
contraindications, 171
dosage, 169t
drug interactions, 171
efficacy, 170
formulations, 170
indications for, 170
IOP reduction with, 169t
side effects, 171, 172t-173t
for surgery-associated IOP spikes, 237, 238
- Aqueous humor, functions of, 112
- Aqueous humor outflow
conventional pathway, 91, 112-113
medical enhancement of, 114
increasing, 110t, 112-121
advantages of, 112
drugs for, 113t, 114
external drainage for, 116-118, 117
future agents for, 194, 195t
internal drainage for, 118-119
laser surgery for, 110t, 114-116
shunt implants for, 116-118, 117
surgery for, 114-121
nonconventional (uveoscleral) pathway, 91, 113
medical enhancement of, 114
suppression by pilocarpine, 114

- Aqueous humor outflow (*continued*)
 obstruction of, 91, 112, 252
 in exfoliation glaucoma, 105
 in PACG, 225, 227t
- Aqueous humor production, decreasing, 109-112, 110t
 drugs for, 109-111, 110t
 laser surgery for, 110t, 111-112
 safety of, 112
- Arcuate scotoma, 41, 48, 48
- Argon laser iridoplasty, 228-229, 229
- Argon laser photocoagulation, 251
- Argon laser trabeculoplasty (ALT), 115, 248. See also *Trabeculoplasty*.
 in Glaucoma Laser Trial, 143-148, 144t
 indications for, 248
 treatment sequence (in AGIS), 149-151
- Arrhythmias, 161t, 173t, 184t, 186t
- Asians
 CCT in, 26
 glaucoma incidence and, 99
 glaucoma progression and, 148-149
- Assessment. See *Patient assessment*.
- Asthma
 β -blockers and, 111, 162
 betaxolol use indicated with, 161-162
 from cholinergic agents, 184t
 Cosopt/Combigan contraindicated for, 180
 medications for, 18-19
- Asymmetry
 in NTG case study, 55, 55-63
 in optic disc, 14t, 55
- Autoantibodies, 95
- Autoimmune T cells, 197-198
- Autologous blood injections, 243
- Avastin (bevacizumab), 254
- Axenfeld-Rieger syndrome, 95
- Azopt. See *Brinzolamide*.
- Back pain, 167t, 180t, 187t
- Baerveldt tube implants (shunts), 116-118, 117
- Baltimore Eye Survey, 52, 86-88, 86t
- Barbados Eye Study (BES), 88, 95
- BDNF, 195t, 196
- Beaver Dam Eye Study, 86t, 88
- Benzalkonium chloride, 165, 168
- β -Adrenergic agonists, 109-111. See also *Adrenergic agonists, nonspecific*.
- β -Antagonists. See *β -blockers*.
- β -Blockers, 110t, 159-162, 160t. See also *specific drugs*.
 aqueous humor production and, 109-111
 bronchospasm from, 18
 cardioselective and noncardioselective, 159, 160t
 in combination therapy, 130-131, 131t, 179-181, 182
 contraindications, 162, 203
 diurnal IOP variations and, 127
 dosage, 160t
 drug interactions, 162
 efficacy, 127, 159
 for PACG, 228
 patient compliance issues, 134
 for post-trabeculoplasty IOP spike, 237
 for postoperative bleb leak, 243
 as primary therapy, 130, 220
 side effects, 159-162, 161t, 192t
 cardiovascular, 161t, 162, 180, 181, 203
 ocular, 128, 159-161, 192t
 systemic, 111, 128, 161-162, 161t, 192t, 203
 in treatment algorithm, 218-219
 vs prostaglandin analogues, 164, 203
- Beta zone, 34-35
- Betagan (levobunolol), 110t, 160t, 192t
- Betaxolol (Betoptic S), 110t, 160t
 cautions, 161-162
 dosage, 160t
 in Early Manifest Glaucoma Trial, 152-153
 efficacy, 159
 indication for asthmatics, 161
 persistency of medical therapy, 215
 side effects, 161-162, 161t, 192t
 vs dorzolamide, 174
- Betimol. See *Timolol*.
- Betoptic/Betoptic S. See *Betaxolol*.
- Bevacizumab (Avastin), 254
- Bilberry, 191
- Bimatoprost (Lumigan), 113t, 162-168, 163t. See also *Prostaglandin analogues*.
Xalatan-Lumigan-Travatan (XLT) Study.
 action mechanism, 113t
 conjunctival hyperemia from, 165, 213
 contraindications and warnings, 164, 165
 cystoid macular edema from, 168
 dosage, 163t
 efficacy, 162-164, 163t, 214
 as first-line medication, 164
 indications for, 164
 IOP reduction with, 163t, 209, 211-213, 212, 214
 ocular pigment changes with, 165
 persistency of medical therapy, 215
 response rate with, 210, 210t, 214
 safety, 165, 206
 side effects, 166t-167t, 192t
 ocular, 165, 166t, 192t
 systemic, 167t, 192t
 tolerability, 165, 206, 212
 vs latanoprost, 165, 211-213, 212, 214
 vs timolol, 206
 in Xalatan-Lumigan-Travatan study, 207-210, 209, 210t-211t
- Bistratified (koniocellular) ganglion cells, 43
- Bjerrum scotoma, 41, 48, 48
- Blacks. See *African Americans*.
- Bleb (in filtration surgery), 116-118
 encapsulation, 117, 152
 leaks, postoperative, 242, 243, 248, 249
 massage, 242
 scarring, 241
- Blebitis, 242
- Blepharitis, 172t, 176t, 180t
- Blindness, 85, 101
 aims of refractory glaucoma treatment for, 255
 IOP and, 99, 101
 Olmstead County Study, 101
 patient noncompliance leading to, 131
- Blood flow
 ocular, enhanced, 195t, 197
 to optic nerve/nerve head, 12, 51-52, 104t
 medications enhancing, 197
 testing, 51-52
- Blood pressure
 elevated. See *Hypertension*.
 low, 18, 95, 153. See also *Hypotension*.
 in patient evaluation, 37
- Blue Mountains Eye Study, 88-89
- Blurred vision
 as medication side effect, 166t, 172t, 176t, 180t, 186t
 in PACG, 225
 in patient evaluation, 17
- Bradycardia, 111, 162, 180
- Brimonidine (Alphagan), 110t, 113t, 169t. See also *α_2 -agonists*.
 aqueous outflow and, 111, 113t, 114
 in combination therapy, 131t, 220
 in Combigan (brimonidine/timolol), 179, 180-181
 contraindications and cautions, 171

Brimonidine (Alphagan) (*continued*)

- dosage, 169t
 - drug interactions, 171
 - efficacy, 170-171
 - formulations, 169t, 170, 172t-173t
 - hypotension from, 171
 - indications for, 170
 - IOP reduction with, 169t
 - as neuroprotective agent, 195-196
 - persistency of medical therapy, 215
 - side effects, 171, 172t-173t
 - for surgery-associated IOP spikes, 237, 238
 - tolerability, 171
 - in treatment algorithm, 218-219
 - vs timolol, 170-171, 207, 208t
- Brinzolamide (Azopt), 110t, 174-175, 174t
- contraindications, warnings, and drug interactions, 174-175
 - dosage, 174t
 - efficacy, 174
 - side effects, 174, 176t, 192t
- Bronchitis, 173t, 180t
- Bronchospasm, 161t
- Burning/stinging eyes, 166t, 172t, 176t, 180t, 184t, 186t
- Burnt-out pigmentary glaucoma, 234

C/D ratios. See *Optic cup/disc (C/D) ratios*.

- Caffeine, IOP and, 27
- Calcium antagonists, 162
- Calcium channel blockers, 196
- Caldesmon, 194
- Calpeptin, 195t, 196
- Canaloplasty, 120-121
- Cannabinoids, 194
- Carbachol (Isopto Carbachol), 113t, 114, 182, 183t
- action mechanism, 113t, 114
 - contraindications, 182
 - dosage, 183t
 - indications for, 182
 - IOP reduction with, 183t
 - side effects, 182, 184t
 - tolerability, 182
- Carbonic anhydrase inhibitors, 110t, 131t, 174-178
- allergic reaction to, 176t
 - aqueous humor production and, 109-111
 - in combination therapy, 131t, 174, 182, 220
 - indications for, 174, 175, 178
 - oral, 111, 175-178, 177t
 - contraindications and warnings, 175
 - dosage, 177t
 - indications for, 175, 178
 - side effects, 111, 175, 178, 178t, 193t
 - tolerability, 175, 178
 - for PACG, 175, 228
 - for postoperative bleb leak, 243
 - for trabeculectomy IOP spikes, 237
 - side effects, 128, 175, 176t, 178t, 192t
 - topical, 111, 174-175, 174t
 - combined with prostaglandin analogues, 216, 220
 - contraindications, warnings, and drug interactions, 174-175
 - dosage, 174t
 - efficacy, 174
 - IOP reduction with, 174t
 - side effects, 128, 175, 176t
 - in treatment algorithm, 218-219
- Cardiac arrest/failure, 161t, 162, 180, 186
- Cardiovascular disease, OAG and, 95, 153
- Cardiovascular side effects
- of alpha agonists, 171, 173t
 - of beta blockers, 161t, 162, 180, 181, 203
 - of cholinergic agents, 184t

Cardiovascular side effects (*continued*)

- of epinephrine agents, 186t
 - of hyperosmotic agents, 187t
- Carteolol (Ocupress), 110t, 160t, 192t
- Case studies, POAG, 55-83
- asymmetric NTG, 55, 55-63
 - disc pallor and cupping, 80, 81-83
 - large optic disc size, 76, 77-79
 - paracentral defect/focal RNFL thinning, 64, 65-66
 - suspicious optic disc cupping, 67, 67-75
- Cataracts
- epithelial downgrowth after surgery for, 251
 - from prostaglandin analogues, 166t
 - in surgery-arm of CIGTS, 129
- Catecholamine-depleting drugs, 162
- Central corneal thickness. See *Corneal thickness, central*.
- Chest pain, 167t, 176t
- Children
- brimonidine contraindication for, 171
 - Perkins applanation tonometer for, 23
- Cholinergic agonists, 114, 131t, 182, 183t
- action mechanism, 114
 - in combination therapy, 182
 - contraindications, 182
 - dosage, 183t
 - indications for, 182
 - for PACG, 228
 - side effects, 114, 182, 184t, 192t
 - tolerability, 182
- Chorioretinitis, 104t
- Choroidal detachment, postoperative, 244
- Choroidal effusion, 248
- Choroidal hemorrhage, 244
- Ciliary block (malignant) glaucoma, 230-231
- after ocular surgery, 130t, 230, 230t, 249
 - characteristics/diagnosis, 230, 230t
 - mechanisms of, 230
 - treatment, 231
- Ciliary flush, 227t
- Ciliary neurotrophic factor (CNTF), 195t, 196
- Ciliary processes, surgery involving, 111, 112
- Cirrhosis, 175
- Clinical and research studies, 143-158, 144t-147t, 203-214
- Advanced Glaucoma Intervention Study, 26, 145t, 149-151, 150t
 - Baltimore Eye Survey, 52, 86-88, 86t
 - Barbados Eye Study, 88, 95
 - Beaver Dam Eye Study, 86t, 88
 - Blue Mountains Eye Study, 88-89
 - Collaborative Initial Glaucoma Treatment Study, 128-129, 145t, 151-152
 - Collaborative Normal-Tension Glaucoma Study, 100, 144t, 148-149
 - comparative, 204-214
 - prostaglandin analogues, 207-214
 - prostaglandin analogues vs β -blockers, 204-207
 - Early Manifest Glaucoma Trial, 95, 99-100, 146t, 152-153
 - European Glaucoma Prevention Study, 99
 - Glaucoma Laser Trial, 143-148, 144t
 - Los Angeles Latino Eye Study, 155-156
 - Ocular Hypertension Treatment Study, 25, 99, 146t-147t, 153-155
 - Olmstead County Study, 101
 - Proyecto VER, 89
 - Rotterdam Study, 88
 - Tube versus Trabeculectomy study, 118
 - unilateral, 137-138
- Clonidine, 111, 171
- CME. See *Cystoid macular edema*.
- CNTF (ciliary neurotrophic factor), 195t, 196
- Cold hands, optic neuropathy and, 96
- Collaborative Initial Glaucoma Treatment Study (CIGTS), 128-129, 145t, 151-152
- Collaborative Normal-Tension Glaucoma Study (CNTGS), 100, 144t, 148-149
- Collagen cross-linking, 26

- Color vision testing, 50-51
- Combigan (brimonidine and timolol), 179, 180-181
 - contraindications, 181
 - efficacy, 181
 - side effects, 180t, 181, 193t
 - in treatment algorithm, 218-219
- Combination agents, 178-181, 220
 - advantages and disadvantages of, 178-179
 - bioavailability of agents in, 179
 - Combigan, 179, 180-181
 - Cosopt, 179-180
 - triple combination therapy (amyloid-beta pathway), 195t, 196-197
- Combining medical therapies, 129-131, 131t
- Compliance/adherence to drug therapy, 131-134, 133t, 216
 - adjunctive/additive therapy and, 216
 - dosing and, 132, 134
 - factors in, 133t
 - obstacles to, 132, 133t
 - optimizing, 132, 134t
 - side effects and, 132
- Confocal scanning laser ophthalmoscopy, 50
- Confrontational visual field testing, 45
- Confusion, as medication side effect, 161t, 178t, 187t
- Congenital colobomas, 103
- Congenital glaucomas, 52
- Conjunctival hyperemia. *See Hyperemia.*
- Conjunctivitis
 - from α_2 -agonists, 171, 172t
 - from carbonic anhydrase inhibitors, 176t
 - from cholinergic agents, 184t
 - from Cosopt and Combigan, 180t
 - from epinephrine compounds, 186t
 - from prostaglandin analogues, 166t
- Contact lens, soft, 243
- Contrast sensitivity testing, 51
- Cop-1, 195t, 197-198
- Cornea
 - biomechanics of, 22, 26
 - collagen cross-linking procedures, 26
 - edema of, 26, 130t, 227t
 - flattening of, in applanation tonometry, 21, 233
 - hysteresis of, 24
 - pigment dispersion syndrome and, 105
 - slit-lamp examination of, 29t
 - thickness of. *See Corneal thickness, central.*
- Corneal pachymetry, 26, 104
- Corneal thickness, central (CCT), 25-26, 155-156
 - diagnosis pitfalls and, 22, 25-26, 104
 - IOP and (in OHTS), 25-26, 147t, 155-156
 - race and, 26
- Corticosteroids
 - after incisional surgery, 242
 - glaucoma induced by, 19, 106, 235, 242
 - for herpes-associated keratouveitis, 253
 - IOP and, 19, 27, 233, 235
 - monitoring recommendations, 19, 235
 - normal eye response to, 234
 - ocular inflammation and, 252
 - in patient evaluation, 19, 37
 - for post-trabeculoplasty IOP spike, 237
- Cosopt (dorzolamide and timolol), 179-180
 - contraindications, 180
 - efficacy and tolerability, 179
 - indications for, 179
 - side effects, 180t, 193t
 - in treatment algorithm, 218-219
- Cost of medication, patient compliance and, 133t
- Cough, from β -blockers, 161t
- Cup/disc (C/D) ratios, 32-33
 - in case studies, 58, 70
 - central corneal thickness and, 26
- Cup, optic. *See Optic cup.*
- Cupping, 11, 12, 41. *See also Optic disc.*
 - association with visual field loss, 41
 - asymmetry of, 36
 - case studies
 - asymmetric cupping, 55, 58
 - profound cupping and pallor, 80, 81-83
 - suspicious cupping, 67, 67-75
 - glaucomatous, 11, 33-34, 33, 34, 41
 - nonglaucomatous, 103
 - timing of, vs pallor, 103
- Cyclodestruction, 111-112, 249, 255
- Cycloplegic agents, 112, 230t, 231, 253
- Cystoid macular edema (CME), 168
 - prostaglandin analogues and, 164, 166t, 168, 192t, 217
- Cytokines, 95
- Depression, beta blockers and, 161t
- Dermatitis, 176t
- Dexamethasone, 242
- Diabetes mellitus, POAG risk and, 18
- Diabetic retinopathy, 254
- Diagnosis, 17-39, 103-107. *See also Patient assessment.*
 - assessment and testing, 17-39
 - early, 45
 - of PACG, 225-227, 227t
 - pitfalls of, 103-107
 - abnormal central corneal thickness, 104
 - anterior chamber depth, 106
 - non-glaucomatous optic neuropathy, 103, 104t
 - unilateral glaucoma, 104-106
 - vision loss prior to, 17
- Diamox, Diamox Sequels. *See Acetazolamide.*
- Diarrhea, 178t, 184t, 187t
- Diathermy, 111
- Diclofenac, 242
- Digitalis, 162
- Diode lasers, 111-112
- Dipivefrin (Propine)
 - action mechanisms, 110t, 113t, 184-185, 185t
 - contraindications, 185
 - dosage, 185t
 - IOP reduction with, 185t
 - side effects, 186, 186t, 192t
- Disc, optic. *See Optic disc.*
- Diurnal IOP variation, 27-28, 125-127, 126
 - controlling, 125-127
- Dizziness, 161t, 173t, 176t
- Dorzolamide (Trusopt), 110t, 174-175, 174t
 - in combination therapy, 131t, 220
 - in Cosopt (dorzolamide/timolol), 179-180, 180t
 - contraindications, warnings, and drug interactions, 174-175
 - diurnal IOP and, 127
 - dosage, 174t
 - efficacy, 174, 197
 - indications for, 174
 - IOP reduction with, 174, 174t
 - persistency of medical therapy, 215
 - side effects, 174, 176t, 192t
- Drugs for glaucoma, 159-190. *See also specific drugs and drug classes.*
 - action mechanisms of, 109, 110t, 159, 247
 - classes of, 110t, 131t
 - α_2 -agonists, 168-171
 - β -blockers, 159-162
 - carbonic anhydrase inhibitors, 174-178
 - cholinergic agonists, 182
 - combination agents, 178-181
 - hyperosmotic agents, 185-186
 - nonspecific adrenergic agonists, 184-185
 - prostaglandin analogues, 162-168

- Drugs for glaucoma (*continued*)
- combination therapies with, 129-131, 131t, 178-181, 193t
 - compliance/adherence issues, 131-134, 133t, 134t
 - diurnal IOP variation, controlling, 125-127, 126
 - dosing, patient compliance and, 132, 134
 - efficacy
 - balancing with tolerability, 127-128
 - at trough concentrations, 127
 - unilateral trials of, 137-138, 216-217
 - as first-line therapy, 109, 128, 247
 - general considerations, 125-141
 - persistence of therapy, 215
 - safety of, 128-129, 130t
 - side effects, 128, 192t-193t. See also *specific drugs and drug classes*.
 - ocular and systemic, 192t-193t
 - patient noncompliance and, 132, 133t
 - systemic, reducing, 138-139
 - systemic absorption of, reducing, 138-139
 - target IOP range, setting, 125, 134-137
 - therapeutic index for, 128
 - unilateral trials of, 137-138, 216-217
- Dry eyes, 166t, 172t, 176t, 180t
- Dry mouth, 173t, 176t
- Dyspnea, 161t, 176t
- Early Manifest Glaucoma Trial, 95, 99-100, 146t, 152-153
- Echothiophate iodide, 113t
- Edema
 - conjunctival, 176t
 - corneal, 26, 130t, 227t
 - cystoid macular. See *Cystoid macular edema*.
 - pulmonary, 187t
- Elderly patients. See also *Age*.
 - aggressive therapy for, 137
 - glaucoma incidence and prevalence in, 85, 88-89
 - life expectancy and RCG death, 136-137
- Endocyclophotocoagulation (ECP), 112
- Endophthalmitis, 242, 249
- Epinephrine. See *Dipivefrin*.
- Epithelial downgrowth, 251-252
- Erythropoietin (EPO), 195t, 197
- Ethnicity. See *Race/ethnicity*.
- Etiology of POAG, 91-98
 - genetic factors, 13-14, 19, 93-95
 - immune system factors, 95
 - IOP and humor outflow obstruction, 91
 - optic neuropathy, 92-93
 - systemic factors, 96
 - vascular factors, 95
- European Glaucoma Prevention Study (EGPS), 99
- Event analysis, 44
- Ex-Press mini shunt, 118
- Examinations. See *Patient assessment*.
- Excitotoxins, 12-13
 - protection against, 196
- Exfoliation syndrome, 105, 234-235
 - genetic factors in, 95, 234-235
 - post-surgery IOP spikes and, 237
- Eye pain
 - as medication side effect, 166t, 172t
 - in PACG, 225
 - in patient evaluation, 17
- Eye patch, 243
- Eyelash growth/changes, 165, 166t, 172t, 192t, 204, 213
- Eyelid skin darkening, 166t, 192t, 204
- Family history of glaucoma, 19, 93-95
 - screening for, 52
- Fatigue/drowsiness, 173t, 178t
- Fibrillar material, in exfoliation syndrome, 105, 235
- Fibroblasts, bleb scarring and, 241
- Filtration surgery, 116, 118-119
 - adjunctive antimetabolites after, 241-242
 - advantages and disadvantages of, 119
 - bleb leaks after, 242, 243, 248, 249
 - bleb massage after, 242
 - bleb scarring after, 241
 - complications of, 241-246
 - as first-line therapy, 128-129
 - indications for, 251
 - nonpenetrating, 118-119
 - penetrating, 116
 - for refractory glaucoma, 251
 - vitamin E as adjunct to, 194
- Fluocinolone acetonide intravitreal implant, 253
- 5-Fluorouracil (5-FU), 241-242
- Flurbiprofen, 242
- Foreign-body sensation, 166t, 172t
- Frequency-doubling technology (FDT), 45
- Fuchs' corneal endothelial dystrophy, 29t
- Ganglion cells
 - bistratified, response to light, 43
 - retinal. See *Retinal ganglion cells*.
- Gastrointestinal disorders, from cholinergic agents, 184t
- GDNF, 196
- GDx, 50
- Gene therapy (with CNTF), 196
- Genetic factors, 13-14, 93-95
 - in exfoliation syndrome, 95, 234-235
 - in POAG, 13-14, 19, 52, 93-95
 - specific genes, 94-95, 234-235
- Genetic testing, 52
- Ginkgo biloba, 191
- Glaucoma
 - definition of, 11-12, 85
 - early signs of, 36, 41, 45
 - genetic factors in, 13-14, 19, 93-95
 - multifactorial nature of, 12-14, 93-94
 - progression of
 - efficacy of treatment on, 99-100, 153
 - index, 44
 - markers of, 35, 100, 153
 - treatment effect on, 99-100
- Glaucoma hemifield test, 46t
- Glaucoma Laser Trial (GLT), 143-148, 144t
- Glaucoma progression index (GPI), 44
- Glaucomatous optic neuropathy (GON). See *Optic neuropathy*.
- GLC1G gene, 94
- Globe, massage/pressure after filtration surgery, 242
- Glucosaminoglycan production, 241
- Glutamate, excessive, 12-13
- Glutamate neurotoxicity protection, 13, 196
- Glycerin (Osmoglyn), 185-186, 187t
- Gold micro-shunt, 119-120
- Goldmann applanation tonometry, 21-22
 - central corneal thickness and, 22, 26, 104, 155
- Goldmann gonioscopy, 28
- Goldmann perimetry testing, 44-45
- Gonioscopy, 28-31, 30, 106
 - clinical findings on, 31, 227t
 - direct vs indirect, 28, 30
 - four-mirror indentation, 226
 - grading systems, 31, 31t
 - of pigmentary dispersion syndrome, 233
- Halos, in PACG, 225
- Headache, 161t, 167t, 173t, 176t, 184t, 187t, 192t
- Hearing dysfunction, 178t
- Heart block, 161t, 162, 180, 181

Heart failure, 186
 Heidelberg Retinal Tomograph. See *HRT*.
 Hemifield test, 46t
 Hemorrhage
 choroidal, 244
 intracranial, 187t
 of optic disc, 35, 100, 153
 from surgery, 129, 130t, 248
 from trauma, 253
 Hepatic disease, 175, 186
 Herbal medicine, 191
 Herpes simplex and herpes zoster, 253
 Herpes simplex keratitis, prostaglandin analogues and, 164, 217
 Hispanic population, POAG incidence/prevalence in, 85, 89, 155-156
 History
 family, 19, 93-95
 medical, 18-19
 ocular, 17-18
 HRT (Heidelberg Retinal Tomograph), 50
 in case study on asymmetric NTG, 55, 60-63
 in case study on large disc size, 76, 77-79
 in case study on suspicious disc cupping, 72
 Hruby lens, 32
 Humphrey threshold testing programs, 42, 42, 44
 in case study on asymmetric NTG, 55, 56-59
 in case study on suspicious disc cupping, 68-69
 Hyperchloremic acidosis, 175
 Hyperemia
 α_2 -agonists and, 172t
 carbonic anhydrase inhibitors and, 176t
 Cosopt and, 180t
 in PACG, 227t
 prostaglandin analogues and, 165-168, 166t, 192t, 209-210, 213-214
 Hyperosmotic agents, 185-186, 187t
 dosage, 187t
 indications for, 185-186
 for PACG, 228
 for post-trabeculoplasty IOP spikes, 237
 side effects, 186, 187t
 vitamins as, 191-194
 Hypertension
 as medication side effect, 161t, 173t, 186t
 OAG risk and, 18
 ocular. See *Intraocular pressure; Ocular Hypertension Treatment Study*.
 HypHEMA
 glaucoma from, 253
 postsurgical, 152
 Hypotension, 111, 161t, 171, 184t
 Hypotensive therapy, 230t, 231
 Hypotony
 management of, 243
 from mitomycin-C or 5-FU, 241
 postoperative, 112, 118, 129, 243, 248
 Immune system factors in POAG, 95
 Immune system modulation, 195t, 197-198
 Implants
 fluocinolone acetonide intravitreal, 253
 shunt/tube. See *Shunt implants*.
 Incidence of POAG, 85-89, 86t, 87
 Incisional surgery, 116-118. See also *Surgery for glaucoma*.
 adjunctive antimetabolites after, 241-242
 anti-inflammatory agents after, 242
 bleb encapsulation after, 117
 bleb leaks after, 242, 243, 248, 249
 bleb massage after, 242
 bleb scarring after, 241
 choroidal detachment after, 244
 complications of, 129, 130t, 241-246
 early, 248-249
 late, 249
 Incisional surgery (*continued*)
 for refractory glaucoma, 248-249
 vs laser surgery, 248-249
 Indentation gonioscopy, 28, 226
 Indentation (Schiotz) tonometry, 24-25
 Infants
 brimonidine contraindication for, 171
 Perkins applanation tonometer for, 23
 Inflammation, ocular
 after incisional surgery, 242, 248
 after laser procedures, 238-239
 glaucoma associated with, 252-253
 Inheritance. See *Genetic factors*.
 Insomnia, beta blockers and, 161t
 Intracranial hemorrhage, 187t
 Intraocular pressure (IOP), 11, 20-21, 20
 abnormal, 20-21, 20
 blindness risk and, 99, 101
 blood pressure compensation and, 52
 blood pressure elevation and, 18
 borderline, 20-21, 20
 caffeine intake and, 27
 central corneal thickness and, 25-26, 147t, 155-156
 corticosteroids and, 19, 27
 in diagnosis of POAG, 11, 14, 17
 diurnal variations in, 26-27, 125-127, 126
 elevated
 causes of, 91
 in ciliary block glaucoma, 230, 230t
 corticosteroids and, 19, 27
 exfoliation glaucoma and, 105
 glaucoma definition and, 11
 glaucoma diagnosis and, 11, 14, 17
 glaucoma etiology and, 91, 99, 105
 glaucoma risk and, 88, 89, 153
 with no glaucoma signs, 99
 in PACG, 225, 227t
 pigment dispersion syndrome and, 105
 steroid-induced, 106
 trauma-induced, 253
 fluctuations in, 17, 127, 215, 233
 in general population, 20-21, 20
 measurement of, 21-25. See also *Tonometry/tonometers*.
 central corneal thickness and, 25-26, 147t, 155-156
 other factors and, 27
 slit-lamp examination in, 28, 29t
 nocturnal elevation in, 125, 126, 127
 normal, 20-21, 20. See also *Normal-pressure glaucoma*.
 in OAG, 11, 20, 88, 89, 99
 optic nerve head blood flow and, 92-93, 92
 optic neuropathy and, 92-93
 reduction of. See also *Drugs for glaucoma: Treatment of glaucoma*.
 balancing efficacy and tolerability, 127-128
 combining therapies for, 129-131, 131t
 controlling diurnal variation, 125-127, 126
 drugs for, 110t, 113t
 efficacy at trough drug concentration, 127
 glaucoma progression and, 99-100, 136
 ONH blood flow and, 52
 patient compliance in, 131-134, 133t, 134t
 safety of, 112
 surgery for, 111-112, 114-121
 surgery vs medication for, 128-129
 topical medications, systemic absorption of, 138-139
 unilateral trials of, 137-138, 216-217
 spikes in, 112, 235, 237-238
 stress and, 27
 target pressure, 125, 134-137
 absolute number vs percentage reduction, 136
 definition of, 135

- Intraocular pressure (IOP) (*continued*)
 visual field defects and, 100, 149-151, 150t
 water consumption and, 27
- IOL Master, 227
- Iopidine. See *Apraclonidine*.
- Iridocorneal recess, angular width of, 31, 31t
- Iridocyclitis, 164, 252
- Iridoplasty, laser, 228-229, 229, 230
 complications of, 238, 239
- Iridotomy, laser, 228
 complication of, 238, 239
 for pigmentary dispersion syndrome, 233-234
- Iris
 contour, Spaeth grading system and, 31
 discoloration, 166t
 in PACG, 225, 226
 pigment changes with prostaglandin analogues, 165, 166t, 192t, 214
 plateau iris, 229-230
 slit-lamp examination of, 29t
- Iritis, 166t, 239
- Isopto Carbachol. See *Carbachol*.
- Isopto Carpine. See *Pilocarpine*.
- Istalol. See *Timolol*.
- Joint pain, 167t
- Juvenile open-angle glaucoma, 52, 93, 94
- Keratitis
 from herpes simplex, 164, 217
 as medication side effect, 176t, 184t, 192t
- Keratouveitis, herpes virus-related, 253
- Kidney disease, 175
- Kidney stones, 176t, 178t
- Kinetic testing, 44-45
- Koepple gonioleus, 28, 30
- Koniocellular (bistratified) ganglion cells, 43
- Krukenberg's spindle, 105, 233
- Lacrimal drainage system, 138-139
- Lamina cribrosa, 32, 92, 92
- Laser iridoplasty, 228-229, 229, 230
 complication of, 238, 239
- Laser iridotomy, 228
 complications of, 238, 239
 for pigmentary dispersion syndrome, 233-234
- Laser ophthalmoscopy, 50
- Laser surgery, 111-112, 114-116. See also *Surgery for glaucoma; Trabeculoplasty*.
 for ciliary block glaucoma, 231
 complications following, 112, 130t, 237-240, 248
 to decrease aqueous humor production, 110t, 111-112
 for exfoliation glaucoma, 235
 as first-line therapy, 116, 128-129, 148
 to increase aqueous humor outflow, 110t, 114-116
 indications for, 111, 115-116
 IOP reduction with, 248
 for PACG, 228-229, 229
 for pigmentary dispersion syndrome, 233-234
 for refractory glaucoma, 147-148
 treatment sequence (in AGIS), 149-151
 types of
 argon laser trabeculoplasty, 115
 cyclodestruction, 111-112
 selective laser trabeculoplasty, 115-116
 trabeculoplasty, 114-116
 vs incisional surgery, 248-249
- Lasik, IOP measurements and, 26
- Latanoprost (Xalatan), 113t, 162-168, 163t. See also *Prostaglandin analogues*;
Xalatan-Lumigan-Travatan (XLT) study.
 action mechanism, 113t
 in combination therapy, 131t, 220
- Latanoprost (Xalatan) (*continued*)
 conjunctival hyperemia from, 165
 lower rate of, 209-210, 213-214
 contraindications and warnings, 164, 165
 cystoid macular edema from, 168
 diurnal IOP variations and, 127
 dosage, 127, 163t
 efficacy, 127, 162-164, 204-206, 214
 as first-line medication, 164
 indications for, 164
 IOP reduction with, 163t, 164, 209, 211, 212, 214
 ocular pigment changes with, 165, 214
 persistency of medical therapy, 215
 response rate with, 206, 210, 210t, 214
 side effects, 166t-167t, 192t
 ocular, 165, 166t, 192t
 systemic, 167t, 192t
 tolerability, 210, 212
 in treatment algorithm, 218-219
 vs bimatoprost, 165, 211-213, 212, 214
 vs timolol, 164, 204-206, 205
 vs travoprost, 165, 213-214, 213
 in Xalatan-Lumigan-Travatan study, 207-210, 209, 210t-211t
- Latrunculin B (LAT-B), 194, 195t
- LEDGF, 196
- Lens extraction, 230, 231
- Lens opacity, 184t, 249
- Lens, slit-lamp examination of, 29t
- Levobunolol (Betagan), 110t, 160t, 192t
- Lid edema, 172t
- Liver disease, 175, 186
- Los Angeles Latino Eye Study (LALES), 155-156
- Lucentis (ranibizumab), 254
- Lumigan. See *Bimatoprost; Xalatan-Lumigan-Travatan (XLT) study*.
- Lysyl oxidase-like 1 (LOXL1) gene, 94-95, 235
- MacKay-Marg tonometry, 22, 23
- Macular edema, cystoid. See *Cystoid macular edema*.
- Maculopathy, from mitomycin-C, 241
- Magnocellular cells, 43, 45
- Malaise, 178t
- Malignant (ciliary block) glaucoma, 230-231, 231t, 249
- Mannitol (Osmitol), 185-186, 187t
- MAO inhibitors, drug interactions with, 171
- Marijuana cigarettes, 194
- Maximum tolerable medical therapy, 131t, 216, 247
- Medical history, 17-19
- Medical management. See *Treatment of glaucoma*.
- Medications for glaucoma. See *Drugs for glaucoma*.
- Memantine, 195t, 196
- Methazolamide (Neptazane), 175-178, 177t
 contraindications and warnings, 175
 delivery/dosage, 177t
 side effects, 178t, 193t
- Metipranolol (OptiPranolol), 110t, 160t
 dosage, 160t
 granulomatous uveitis from, 161
- Migraine, 96, 148
- Minocycline, 195t, 196-197
- Miosis
 from topical cholinergic agents, 184t
 in treatment of PACG, 228
- Miotic agents, 114, 182
- Mitomycin-C (MMC), 118, 241-242
- Monoamine oxidase (MAO) inhibitors, 171
- Muscle pain, 167t
- Mydriasis, 186t
- Myocilin (MYOC) gene mutations, 94
- Myopia
 from cholinergic agents, 184t

- Myopia (*continued*)
 optic disc assessment in, 36
 POAG with, 17-18
 visual field defects and, 17-18
 Myopic retinal degeneration, 104t
- Nasal step defects, 49
 Nasolacrimal occlusion, 138-139
 Natural history of POAG, 99-102
 Nausea/vomiting
 as medication side effect, 176t, 178t, 184t, 187t
 in PACG, 225
 Nd:YAG lasers, 111-112, 115
 for ciliary block glaucoma, 231
 in iridotomy, 238
 for PACG, 228
 Neovascular glaucoma (NVG), 254-255
 laser surgery for, 111
 treatment algorithm for, 256-257
 Neovascularization, 31
 inhibitory agents, 195t, 198
 panretinal photocoagulation for, 238
 Neptazane. *See Methazolamide.*
 Nerve axon atrophy, 92-93
 Nerve Fiber Analyser (NFA), 50
 Nerve fiber bundle defects, nonglaucomatous, 103, 104t
 Nerve fiber layer. *See Retinal nerve fiber layer.*
 Nerve growth factors, 92-93
 Nervous system, β -blocker side effects on, 161t
 Neuronal apoptosis (death), 93
 Neuropathy. *See Optic neuropathy.*
 Neuroprotection, 13
 Neuroprotective agents, 191, 194-197, 195t
 Neuroretinal rim thinning, 41
 Neurotrophins, 195t, 196
 Night vision, 191
 Nightmares, 161t
 Nitric oxide, 196
 Nitric oxide synthase inhibitors, 195t, 196-197
 NMDA receptors, 196
 Noncompliance. *See Compliance/adherence to drug therapy.*
 Noncontact tonometer, 23-24
 Nonspecific adrenergic agonists. *See Adrenergic agonists, nonspecific.*
 Nonsteroidal anti-inflammatory drugs (NSAIDs), 242
 Normal-pressure glaucoma (NPG), 100
 diagnosis of, 11-12, 37, 100
 caution in, 103
 incidence of, 88
 optic disc hemorrhages in, 35
 systemic evaluation in, 37
 visual defect progression in, 17-18
 Normal-tension glaucoma (NTG)
 asymmetric, case study on, 55, 55-63
 clinical study on (CNTGS), 100, 144t, 148-149
 diagnosis of, 11-12
 genetic testing for, 52
 IOP in pathogenesis of, 148-149
 migraine and, 148
 suspects, 12
- Octopus 32 program, 42
 Ocular history, 17-18
 Ocular hypertension, conversion to POAG, 99. *See also Intraocular pressure.*
 Ocular Hypertension Treatment Study (OHTS), 99, 146t, 153-155
 central corneal thickness and IOP in, 25, 147t, 155-156
 Ocular inflammation
 after laser procedure, 238-239
 glaucoma from, 252-253
 Ocular pain. *See Eye pain.*
 Ocular response analyzer (ORA), 24
- Ocupress. *See Carteolol.*
 Olmstead County Study, 101
 Open-angle glaucoma, juvenile, 52, 93, 94
 Open-angle glaucoma, primary (POAG), 11-15
 age and, 14, 86
 case studies, 55-83
 asymmetric NTG, 55, 55-63
 large optic disc size, 76, 77-79
 paracentral defect/focal RNFL thinning, 64, 65-66
 suspicious optic disc cupping, 67, 67-75
 characteristics, 14, 14t
 definition of, 11, 12, 85
 diagnosis, 11, 17-39
 pitfalls in, 103-107, 104t
 early manifest, 99-100
 epidemiology, 85-90
 etiology, 91-98
 genetic factors, 13-14, 19, 93-95
 immune system factors, 95
 IOP and humor outflow obstruction, 91
 optic neuropathy, 92-93, 92
 systemic factors, 96
 vascular factors, 95
 genetic testing for, 52
 incidence and prevalence, 85-89, 86t, 87
 intraocular pressure (IOP) in, 11, 20-21, 20
 normal levels in, 11, 20-21, 20, 88, 89
 natural history, 99-102
 ocular hypertension conversion to, 99
 onset age of, 14, 86
 optic neuropathy in, 11, 14, 14t
 patient variability in, 14
 presentation, 11
 race/ethnicity and, 85-89, 86t, 87
 refractory, 247-259
 as spectrum of diseases, 14
 unilateral, causes of, 104-106
 visual field defects in, 11, 13, 14t
 Open-angle glaucoma, secondary, 233-236
 exfoliation syndrome/pseudoexfoliation glaucoma, 105, 234-235
 pigmentary glaucoma, 233-234
 steroid-associated, 235, 252
 from uveitis, 252
 Ophthalmoscopy, 32
 scanning laser, 50
 Optic cup
 asymmetry of, 36
 atrophy of, 33-34, 33, 34
 characteristics of, 32-34
 definition of, by color/contour, 32-33
 diameter of, 36
 enlargement of, 33, 33, 34
 timing of, vs pallor, 103
 polar notch, 33
 saucerization of, 33-34, 34
 series testing of volumes, 50
 Optic cup/disc (C/D) ratios, 32-33, 36
 central corneal thickness and, 26
 Optic disc, 32-36
 anatomy of, 32
 asymmetrical, 14t
 case study, 55, 55-63
 cupping of, 11, 12, 33-34, 33, 34
 asymmetric (case study), 55, 55
 profound (case study), 80, 81-83
 suspicious (case study), 67, 67-75
 damage, progressive, 14t. *See also Optic neuropathy.*
 definition of, 32
 examination of, 32-36, 41
 hemorrhages of, 35, 100, 153

- Optic disc (*continued*)
 individual variations in, 32
 large (case study), 76, 77-79
 myopic, 46
 normal, 32
 in PACG, 227t
 pallor of, 34, 80, 81-83
 peripapillary changes, 34-35
 retinal nerve fiber layer defects, 35-36
 stereoscopic slit-lamp biomicroscopy of, 32
 topography, 50
 zones alpha and beta, 34-35
- Optic nerve
 atrophy of, 11
 blood flow to, 12, 51-52
 insufficient, 104t
 medications enhancing, 197
 nonglaucomatous damage/defects, 104t
- Optic nerve head
 blood flow to, 12, 51-52
 ischemia of, 92, 104t
 topography/anatomy of, 50, 92
- Optic neuropathy, 11, 14, 14t, 92-93. See also *specific neuropathies*.
 apoptosis and, 93
 elevated IOP and, 92-93, 92
 glaucomatous optic atrophy, 33-34, 33, 34, 92-93
 immune system factors in, 95
 ischemic, 92
 lamina cribrosa changes, 32, 92, 92
 manifestations of, 11, 12-13, 14t
 nonglaucomatous, 103, 104t
 in POAG diagnosis, 17-18, 33-36, 103
 timing of cup enlargement/pallor in, 103
- Optical coherence tomography (OCT), 49-50, 226-227
 in case study on asymmetric NTG, 55, 60-63
 in case study on optic disc cupping/pallor, 80, 82-83
 in case study on suspicious disc cupping, 67, 72-75
- Optineurin (OPTN), 94
- OptiPranolol (metipranolol), 110t, 160t, 161
- Osmitol (mannitol), 185-186, 187t
- Osmoglyn (glycerin), 185-186, 187t
- Oxyphenbutazone, 242
- PACG. See *Angle-closure glaucoma, primary*.
- Pain
 in eye. See *Eye pain*.
 in joints and muscles, 167t
- Pallor, of optic disc, 34, 80, 81
 timing of development of, 103
- Panretinal photocoagulation (PRP), 238, 254, 255
- Paracentral scotomas/defects, 48, 64, 65-66
- Parasympathomimetics. See *Cholinergic agonists*.
- Paresthesia, 178t
- Parvocellular cells, 43
- Pathogenesis (etiology) of POAG, 91-98
- Patient assessment, 17-39. See also *Diagnosis*.
 blurred vision, 17
 family history, 19
 gonioscopy, 28-31, 30
 IOP in, 20-28
 normal, borderline, and abnormal, 20-21, 20
 IOP measurement, 21-28
 central corneal thickness and, 25-26
 corticosteroids and, 19, 27
 diurnal variation in, 26-27
 other factors affecting, 27
 slit-lamp examination in, 28, 29t
 tonometry in, 21-25
 medical history, 18-19
 medications, systemic, 18-19
- Patient assessment (*continued*)
 ocular history, 17-18
 ocular pain, 17
 optic cup
 asymmetry of, 36
 atrophy of, 33-34, 33
 characteristics of, 32-34
 cup/disc ratios, 32-33, 36
 diameter of, 36
 enlargement of, 33, 33, 34
 saucerization of, 33-34, 34
 optic disc, 32-36
 hemorrhages, 35
 myopic, 36
 pallor, 34, 103
 peripapillary changes, 34-35
 retinal nerve fiber layer defects, 35-36
 slit-lamp biomicroscopy, 32
 for PACG, 225-227
 slit-lamp examination in, 28, 29t
 systemic disease/medications, 18-19, 37
 visual acuity measurement, 19
 visual field/acuity defects, 17-18
 visual function testing, 41-54
- Patient compliance. See *Compliance/adherence to drug therapy*.
- PEDF, 196
- Pentacam, 227
- Perimetry testing, 41-45
 interpretation of, 43-44, 46t-47t
- Peripheral anterior synechiae (PAS), 28, 228, 254
- Perkins applanation tonometer, 23
- Peroxisomal targeting signal type 1 receptor (PTS1R), 94
- Persistency of medical therapy, 215
- Phacocytosis, 234
- Photocoagulation
 argon laser, 251
 panretinal, 238, 254, 255
 xenon arc, 111
- Photophobia, 173t, 176t, 251
- Pigmentary dispersion syndrome (PDS), 14, 105, 233-234
 age and, 234
 elevated IOP and, 105, 233
 glaucoma risk in, 105, 233
 gonioscopic detection of, 31
 mechanism of, 233
 treatment of, 233-234
- Pigmentary glaucoma, 233-234
- Pigmentation of iris, changes with prostaglandin analogues, 165, 192t, 204
- Pilocarpine (Isopto Carpine, Pilopine HS), 113t, 182, 183t
 action mechanism, 114
 aqueous outflow and, 113t
 in combination therapy, 182
 contraindications, 182
 dosage, 183t
 efficacy, 128, 182
 indications for, 182
 IOP reduction with, 183t
 for PACG, 228
 for plateau iris ACG, 230
 pupillary block and, 228
 side effects, 128, 182, 184t, 192t
 tolerability, 182
- Pilopine HS. See *Pilocarpine*.
- Plateau iris glaucoma, 229-230
- Platelet aggregation, inhibition of, 191
- Pneumatic tonometer (Pneumotonometer), 23
- POAG. See *Open-angle glaucoma, primary*.
- Polar notch (PN), 33
- Polyuria, 178t
- Prednisolone, 239, 242

Prevalence of POAG, 19, 85-89, 86t, 87
 Primary angle-closure glaucoma (PACG). See *Angle-closure glaucoma, primary*.
 Primary open-angle glaucoma (POAG). See *Open-angle glaucoma, primary*.
 Progression of glaucoma. See *Glaucoma, progression of*.
 Propine. See *Dipivefrin*.
 Prostaglandin analogues, 131t, 162-168, 163t. See also *specific drugs*.
 action mechanism, 114
 advantages of, 131t, 164, 203
 clinical comparisons
 with β -blockers, 204-207, 205
 among prostaglandin analogues, 162-164, 207-214
 Xalatan-Lumigan-Travatan (XLT) study, 207-210, 209, 210t-211t
 in combination therapy, 131, 179, 182, 216, 220
 contraindications, 164, 217
 cystoid macular edema and, 164, 166t, 168, 217
 diurnal IOP cycle and, 164
 dosage/dosing, 163t, 203
 efficacy, 127, 162-164, 165-168, 203-204, 214
 as first-line therapy, 164, 204, 217-220
 pigmentation and ocular tissue changes with, 165, 204, 213
 potency of, 164, 203
 preservative in, 164, 165-168
 as primary therapy, 217-220
 response rate with, 206, 210, 210t, 214
 safety, 165-168, 203-204
 side effects, 165-168, 166t-167t, 192t
 ocular, 165, 166t, 192t, 204
 systemic, 167t, 192t, 203
 tolerability, 165-168, 204, 207
 in treatment algorithm, 218-219
 vs β -blockers, 164, 203, 204-207
 vs timolol, 204-207, 205
 warnings, 165
 Proyecto VER study, 89
 Pruritus, 173t, 176t, 180t
 Pseudoexfoliation syndrome, 95, 105, 135
 glaucoma associated with, 234-235
 gonioscopic detection of, 31
 Pseudophakia, 230t
 Psychotropic drugs, 162
 Pulmonary edema, 187t
 Pupillary block, 225, 226
 reverse, 233, 234
 Pupillary block glaucoma, 225, 226
 cholinergics and, 228
 diagnosis, 225-227
 treatment, 228-229
 Race/ethnicity
 exfoliation syndrome and, 234
 POAG incidence/prevalence and, 85-89, 86t, 87, 99
 Ranibizumab (Lucentis), 254
 Raynaud's phenomenon, 96
 Refractive scotoma, 104t
 Refractory glaucoma, 247, 251-259
 definition of, 247, 251
 epithelial downgrowth and, 251-252
 filtration surgery for, 248-249
 inflammation-associated
 herpes simplex/herpes zoster, 253
 uveitis, 252-253
 laser surgery for, 111, 247-248
 medical therapy insufficiency in, 247-249
 neovascular, 254-255, 256-257
 prostaglandin analogues for, 164
 trabeculoplasty for, 248
 trauma-related, 253
 Reichert ocular response analyzer, 24
 Renal failure/insufficiency/disease, 186, 187t
 Research studies. See *Clinical and research studies*.
 Respiratory side effects, 161t, 162, 167t, 180
 Retinal detachment, 184t
 Retinal ganglion cells (RGCs)
 death of, 93, 136-137
 neuroprotective agents for, 194-197, 195t
 in POAG definition, 11
 SWAP algorithm for testing, 43
 types of, 43
 Retinal nerve fiber layer (RNFL)
 case studies
 asymmetric NTG, 60-63
 large disc size, 76, 77-79
 suspicious disc cupping, 72-75
 defects in, 35-36, 41, 49
 color vision and, 50
 laser damage to, 104t
 measurements, 49-50
 progressive damage to, 14t
 thickness of, 49
 visual field loss prediction by, 49
 Retinal photocoagulation. See *Panretinal photocoagulation*.
 Rho-kinase (ROCK) inhibitors, 194, 195t
 Ripcord stent technique, 117
 Risk factors for glaucoma
 age, 85-89, 87, 137, 153
 cardiovascular disease, 153
 diabetes, 18
 genetic, 52, 93-95
 IOP elevation, 12, 88, 89, 153
 IOP fluctuation, 127, 215
 low blood pressure, 18, 95, 153
 low vascular perfusion pressure, 92, 95, 153
 pigment dispersion syndrome, 105
 predictive calculator for, 155
 race, 85-89, 86t, 87
 ROCK (rho-kinase) inhibitors, 194
 Rotterdam Study, 88
 Safety of treatment options, 128-129, 130t
 Sampaolesi's line, 234
 Saucerization, 33-34, 34
 Scanning laser Doppler flowmetry, 51-52
 Scanning laser ophthalmoscopy, 50
 Scanning laser polarimetry (NFA/GDx), 50
 Scanning peripheral anterior chamber (SPAC) depth analyzer, 227
 Scheimpflug photography, 227
 Schiøtz (indentation) tonometry, 24-25
 Schlemm's canal
 in aqueous outflow, 91, 113
 in nonpenetrating filtration surgery, 118-119
 Schwalbe's line, 234
 Sclerectomy, deep, 249
 Scleritis, from uveitis, 252
 Scotomas, 41, 48, 48, 104t
 Secondary open-angle glaucoma, 233-236
 pigmentary glaucoma, 233-234
 pseudoexfoliation glaucoma, 105, 234-235
 Selective laser trabeculoplasty (SLT), 115-116, 248
 Semiconductor diode lasers, 111-112
 Shaffer grading system, 31, 31t
 Short-wavelength automated perimetry (SWAP), 43, 51
 case study on paracentral defect, 64, 65-66
 Shunt implants, 116-118, 117, 119-120
 Ahmed and Baerveldt, 116-118, 117
 for epithelial downgrowth, 251
 Ex-Press mini, 118
 for refractory glaucoma, 249, 251
 SOLX gold micro-shunt, 119-120
 vs filtration surgery, 116
 vs trabeculectomy, 118

Simmons shell, 243
 Single nucleotide polymorphisms (SNPs), 94, 234-235
 SITA (Swedish Interactive Threshold Algorithm), 43
 Sleep disorders, beta blockers and, 161t
 Slit-lamp examination, 28, 29t
 SOLX gold micro-shunt, 119-120
 Somnolence, 161t, 171
 Spaeth grading system, 31
 Spatial contrast sensitivity, 51
 Static threshold testing, 41-44, 42
 "event" vs "trend" analysis, 44
 interpretation of, 43-44, 46t-47t
 Step defects, 49
 Steroids. *See also Corticosteroids.*
 steroid-induced glaucoma, 19, 106, 235, 242, 252
 topical, for complications of laser surgery, 112, 237, 239, 242
 Stevens-Johnson syndrome, 175
 Stinging/burning eyes. *See Burning/stinging eyes.*
 Stress
 AACG and, 27
 IOP and, 27
 Studies of glaucoma. *See Clinical and research studies.*
 Suprarenal gland failure, 175
 Surgery for glaucoma, 111-112, 114-121. *See also specific types of surgery.*
 benefits of, vs medication, 128-129
 canaloplasty, 120-121
 choice of, 247-248
 ciliary block glaucoma after, 249
 complications of, 112, 129, 130t, 152
 incisional surgery, 241-246
 laser procedures, 112, 237-240, 248
 to decrease aqueous humor production, 110t, 111-112
 to enhance outflow, 110t, 114-121
 newer modalities, 119-121
 through external drainage (shunts), 116-118, 117
 through internal drainage, 118-119
 trabeculoplasty, 114-116
 filtration, 116, 118-119
 as first-line therapy, 128-129
 nonpenetrating, 118-119, 249
 for refractory glaucoma, 248-249
 treatment sequence, vs medication first, 151-152
 vitamin E as adjunct to, 194
 as first-line therapy, 128-129
 incisional, 116-118
 adjunctive antimetabolites after, 241-242
 complications of, 129, 130t, 241-246, 248-249
 endocyclophotocoagulation, 112
 vs laser surgery, 248-249
 indications for, 247-249
 laser, 110t, 111-112, 114-116
 complications of, 130t, 237-240
 for PACG, 228-229, 229
 for refractory glaucoma, 247-248
 vs incisional surgery, 247-248
 maximum tolerable medical therapy vs, 216, 247
 newer modalities, 119-121
 for PACG, 228-229, 229
 safety of, vs medications, 128-129, 130t
 shunt implants, 116-118, 117, 119-120, 249
 trabectome, 119
 trabeculectomy, 116, 248-249
 trabeculoplasty, 114-116
 Sutures, in canaloplasty, 120-122
 SWAP. *See Short-wavelength automated perimetry.*
 Sweating, from topical cholinergic agents, 184t
 Swedish Interactive Threshold Algorithm (SITA), 43
 Sympathomimetics. *See Adrenergic agonists, nonspecific.*
 Syncope, 130t, 161t, 184t
 Synecchia
 formation after laser procedures, 239
 in PACG, 226, 228
 peripheral anterior (PAS), 28, 228, 254
 Systemic absorption of medications, reducing, 138-139
 Systemic disease/medications, 18-19, 36-37
 T-cell based vaccination, 195t, 197-198
 Tachycardia, 186t
 Tachyphylaxis, 170
 Tangent screen testing, 45
 Taste abnormalities, 173t, 176t, 178t, 180t
 Tear flow, medication effects on, 173t, 176t, 184t
 Temporal contrast sensitivity, 51
 Temporal wedge/step defect, 49
 Testing. *See Visual function testing.*
 Tetrahydrocannabinol (THC), 194
 Therapeutic index, 128
 Threshold testing, static, 41-44, 42
 Timolol (Betimol, Istalol, Timoptic), 110t, 111, 160t
 in combination therapy, 130-131, 131t, 159, 174
 in Combigan (brimonidine/timolol), 179, 180-181
 in Cosopt (dorzolamide/timolol), 179-180, 180t
 diurnal IOP and, 127
 dosage, 160t
 efficacy, 159
 formulations, 160t
 in Glaucoma Laser Trial, 143
 persistence of medical therapy, 215
 as primary therapy, 130, 159, 220
 side effects, 192t
 in treatment algorithm, 218-219
 vs α -agonists, 170-171
 vs argon laser trabeculoplasty, 143-148
 vs bimatoprost, 206
 vs brimonidine, 170-171, 207, 208t
 vs dorzolamide, 174
 vs latanoprost, 164, 204-206, 205
 vs travoprost, 206-207
 Timoptic, Timoptic-XE. *See Timolol.*
 Tinnitus, 178t
 TNF- α , immune therapy agents affecting, 195t, 197
 Tonometry/tonometers, 21-25
 air-puff (noncontact), 23-24
 applanation, 21-22
 central corneal thickness and, 25-26
 dynamic contour, 24
 Goldmann, 21-22, 26
 MacKay-Marg, 22, 23
 Perkins, 23
 pneumatic, 23
 rebound, 24
 Reichert ocular response analyzer, 24
 Schiotz (indentation), 24-25
 Tonopen, 21, 22-23
 Toxic metabolites, removal by aqueous humor outflow, 112
 Trabectome, 119
 Trabecular meshwork (TM)
 aqueous humor outflow and, 113, 252
 blockage of, 11, 91
 in exfoliation syndrome, 31, 234
 pigmentation of, 31, 233
 in uveitis, 252
 Trabeculectomy, 116, 248-249
 complications from, 248-249
 as first-line therapy, 129
 success rate, 248
 treatment sequence
 vs ALT first (in AGIS), 149-151
 vs medication first (in CIGTS), 151-152
 vs shunts (TVT study), 118

- Trabeculoplasty, 114-116
 argon laser (ALT), 115, 143-148, 144t
 treatment sequence (in AGIS), 149-151
 complications of, 130t, 239
 for exfoliation glaucoma, 235
 as first-line therapy, 148
 indications for, 115-116
 IOP spike after, 235, 237
 for pigmentary dispersion syndrome, 233
 for refractory POAG, 248
 selective laser (SLT), 115-116
 vs drugs (EMGT study), 152-153
 vs drugs (timolol, GLT study), 143-148, 144t
- Trauma
 epithelial downgrowth after, 251
 glaucoma from, 106, 253
 visual field/nerve fiber bundle defects from, 104t
- Travatan, Travatan Z. See *Travoprost; Xalatan-Lumigan-Travatan (XLT) study*.
- Travoprost (Travatan, Travatan Z), 113t, 162-168. See also *Prostaglandin analogues*;
Xalatan-Lumigan-Travatan (XLT) study.
 aqueous outflow and, 113t
 conjunctival hyperemia from, 165, 213-214
 contraindications and warnings, 164, 165
 cystoid macular edema from, 168
 dosage, 163t
 efficacy, 162-164, 207, 214
 formulations, 163t, 165-168
 indications for, 164
 IOP reduction with, 163t, 209, 213, 214
 ocular pigment changes with, 165
 persistency of medical therapy, 215
 preservative in, 165-168
 response rate with, 210, 210t, 214
 safety, 207
 side effects, 165-168, 166t-167t, 192t
 ocular, 165, 166t, 192t
 systemic, 167t, 192t
 tolerability, 165-168, 207
 vs latanoprost, 165, 213-214, 213
 vs timolol, 206-207
 in Xalatan-Lumigan-Travatan study, 207-210, 209, 210t-211t
- Treatment of glaucoma, 109-124, 110t, 181-201
 adjunctive/additive therapy in, 216, 220
 aggressive initial therapy, 129
 algorithm for, 217-220, 218-219
 alternative medicines, 191-194
 antioxidants, 191
 cannabinoids, 194
 herbal medicines, 191
 vitamins, 191-194
 choosing treatment, criteria for, 131t, 156, 215, 217
 compliance/adherence issues, 131-134, 133t, 134t, 216
 decreasing aqueous humor production in, 109-112, 110t
 drugs for, 109-111, 110t
 laser surgery for, 110t
 drugs for. See *Drugs for glaucoma*.
 efficacy in reducing glaucoma progression, 99-100, 153
 future strategies, 194-198, 195t
 anti-angiogenic agents, 195t, 198
 enhanced aqueous outflow, 194, 195t
 enhanced ocular blood flow, 195t, 197
 immune system modulation, 195t, 197-198
 neuroprotective agents, 194-197, 195t
 general considerations, 125-141
 balancing efficacy and tolerability, 127-128
 combining therapies, 129-131, 131t
 compliance/adherence issues, 131-134, 133t, 134t
 diurnal IOP variations, 125-127, 126
 efficacy at trough drug concentrations, 127
 safety of treatment options, 128-129, 130t
- Treatment of glaucoma, general considerations (*continued*)
 selection criteria, summarized, 131t
 systematic absorption of topical drugs, 138-139
 target IOP range, 125, 134-137
 increasing aqueous humor outflow in, 110t, 112-119
 drugs for, 113t, 114
 external drainage for (shunts), 116-118, 117
 internal drainage for, 118-119
 laser surgery for, 110t, 114-116
 maximum tolerable medical therapy, 131t, 216, 247
 modalities of, 109-124, 110t
 neuroprotective agents in, 191, 194-197, 195t
 primary therapy
 β-blockers as, 130, 220
 drugs as, 109, 128, 247
 laser surgery as, 116, 128-129, 148
 prostaglandin analogues as, 164, 204, 217-220
 primary treatment algorithm, 217-220, 218-219
 refractory glaucoma, 247-259
 surgery for. See *Surgery for glaucoma*.
 Trend analysis, 44
 Triple combination therapy, amyloid-beta pathway, 195t, 196-197
 Trough drug concentration, 127
 Trusopt. See *Dorzolamide*.
 Tube implants. See *Shunt implants*.
 Tube versus Trabeculectomy (TVT) study, 118
- Ultrasound biomicroscopy (UBM), 226
 Unilateral glaucoma, 104-106
 Unilateral trials, 137-138, 216-217
 reverse, 217
 Urea (Ureaphil), 185-186, 187t
 Urolithiasis, 176t, 178t
 Urticaria, 176t
 Uveitis, 192t, 252-253
 anterior, 217, 238-239
 granulomatous, metipranolol and, 161
 neovascular glaucoma and, 254
 Uveoscleral outflow, 91, 111, 113
 enhancers of, 113t, 114
 suppression by pilocarpine, 114
- Valsalva's maneuver, 22
 Vascular factors in POAG, 95
 Vascular perfusion pressure, 92, 95, 153
 Vascularization, new. See *Neovascularization*.
 Vasospastic conditions, 96
 Verapamil, topical, 197
 Viscoanalostomy, 249
 Viscoelastic agents, injection of, 243
 Visual acuity
 in diagnosis, 19
 loss of, 17-18, 227t, 241, 249
 measurement of, 19
 reduced, cholinergic agents and, 184t
 Visual disturbance, from α₂-agonists, 173t
 Visual field defects, 11, 13, 14t, 17-18, 41, 48-49. See also *Visual function testing*.
 altitudinal, 49
 arcuate (Bjerrum) scotoma, 41, 48, 48
 asymmetric (case study), 55, 55-63
 blindness risk and, 101
 central, 51
 central corneal thickness and, 26
 early prediction of, 51
 glaucomatous, 48-49
 interpretation of data, 43-44, 46t-47t
 IOP and, 100, 149-151, 150t
 kinetic testing, 44-45
 nasal step, 49
 nerve fiber bundle, 104t

Visual field defects (*continued*)
non-glaucomatous causes, 103, 104t
in PACG, 227t
paracentral, 48, 64, 65-66
patient-reported, 17-18
peripheral, 51
in POAG, 11, 13, 14t
retinal nerve fiber layer, 41
scotomas, 41, 48, 48
temporal wedge/step, 49
testing for. See *Visual function testing*.
trauma and, 104t

Visual field indices, 46t

Visual function testing, 41-54
Amsler grid, 51
blood flow testing, 51-52
color vision, 50-51
confocal scanning laser ophthalmoscopy, 50
confrontational visual field testing, 45
contrast sensitivity, 51
event analysis, 44
frequency-doubling technology (FDT), 45
genetic testing, 52
glaucoma hemifield test, 46t
glaucoma progression index (GPI), 44
Goldmann perimetry testing, 44-45
Heidelberg Retinal Tomograph (HRT), 50
indices in, 46t
interpretation of, 43-44, 46t-47t
kinetic testing, 44-45
multifocal visually evoked potentials, 51
optic disc topography, 50
optical coherence tomography (OCT), 49-50, 226-227
perimetry, 41-45
reliability of, 46t
scanning laser ophthalmoscopy, 50
scanning laser polarimetry (NFA/GDx), 50
series of cup volumes in, 50
series of fields in, 47t
short-wavelength automated perimetry (SWAP), 43, 51
single-field evaluation, 47t
static threshold testing, 41-44, 42
structural analysis, 49-50
Swedish Interactive Threshold Algorithm (SITA), 43
tangent screen, 45
threshold variability in, 46t
trend analysis, 44
visual function, 50-52

Visually evoked potentials (VEPs), 51, 196

Vitamin C, 191-194
Vitamin E, 194

Water consumption, excess, 27

Xalatan. See *Latanoprost; Xalatan-Lumigan-Travatan (XLT) study*.

Xalatan-Lumigan-Travatan (XLT) study, 207-210
baseline mean 8 AM IOP in, 209, 209
data analyses in, 209-210
ocular hyperemia in, 209-210
patient response rates in, 210, 210t
patient selection in, 207, 210
percentage of patients reaching target IOP on, 210, 211t
structure/design of, 207-209, 214

Xenon arc photocoagulation, 111

Zeiss/Posner lens, 28, 30

Zonular dehiscence, 234